ReviewJournal of cellular and molecular medicine
Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope.
Review in Journal of cellular and molecular medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- What is known on angiogenesis-related rare diseases? A systematic review of literature.Journal of cellular and molecular medicine · 2012Pooled it
- Interference of FZD2 suppresses proliferation, vasculogenic mimicry and stemness in glioma cells via blocking the Notch/NF‑κB signaling pathway.Experimental and therapeutic medicine · 2024Article
- Angioprevention of Urologic Cancers by Plant-Derived Foods.Pharmaceutics · 2022Review
- Investigating the antiangiogenic potential ofSaudi journal of biological sciences · 2020Article
- Circulating Metabolites Originating from Gut Microbiota Control Endothelial Cell Function.Molecules (Basel, Switzerland) · 2019Review
- Review
- Use of Nutraceuticals in Angiogenesis-Dependent Disorders.Molecules (Basel, Switzerland) · 2018Review
- Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Dietary proteins and angiogenesis.Nutrients · 2014Review
- Systems biology for molecular life sciences and its impact in biomedicine.Cellular and molecular life sciences : CMLS · 2013Review
- Article
- Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice.Cancer gene therapy · 2011Article
- Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?Journal of thoracic disease · 2011Article
- Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.British journal of cancer · 2011Review
- Article
- Molecular and clinical aspects of targeting the VEGF pathway in tumors.Journal of oncology · 2010Article
- E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases.Journal of cellular and molecular medicine · 2010Article
- DTD, an anti-inflammatory ditriazine, inhibits angiogenesis in vitro and in vivo.Journal of cellular and molecular medicine · 2008Article
- The anti-angiogenic 8-epipuupehedione behaves as a potential anti-leukaemic compound against HL-60 cells.Journal of cellular and molecular medicine · 2008Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis inhibition has been proposed as a general strategy to fight cancer. However, in spite of the promising preclinical results, a first generation of antiangiogenic compounds yielded poor results in clinical trials. Conceptual errors and mistakes in the design of trials and in the definition of clinical end-points could account for these negative results. In this context of discouraging results, a second generation of antiangiogenic therapies is showing positive results in phases II and III trials at the beginning of the twenty-first century. In fact, several combined treatments with conventional chemotherapy and antiangiogenic compounds have been recently approved. The discovery and pharmacological development of future generations of angiogenesis inhibitors will benefit from further advances in the understanding of the mechanisms involved in human angiogenesis. New styles of trials are necessary, to avoid missing potential therapeutic effects. Different clinical end-points, new surrogate biomarkers and methods of imaging will be helpful in this process. Real efficacy in clinical trials may come with the combined use of antiangiogenic agents with conventional chemotherapy or radiotherapy, and combinations of several antiangiogenic compounds with different mechanisms of action. Finally, the existing antiangiogenic strategies should include other approaches such as vascular targeting or angioprevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.